Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01189 (beta-endorphin)
 21,003 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The release of beta-endorphin-immunoreactivity (beta E-IR) from rat pituitary anterior lobe (AL) quarters, neurointermediate lobes (NILs), and hypothalamic fragments was investigated in vitro. The beta-adrenoceptor agonist isoproterenol (ISO) and the hypothalamic neurohormone corticotropin-releasing factor (CRF) concentration-dependently stimulated the release of beta E-IR from superfused AL quarters and NILs, but not from incubated hypothalamic fragments. Dopamine (DA) inhibited the release of beta E-IR from NILs and hypothalamic tissue in a concentration-dependent manner, whereas it did not affect the release from AL quarters. Arginine8-vasopressin (AVP) stimulated the release of beta E-IR from AL quarters and hypothalamic fragments, but did not affect the release from NILs. The data indicate that the release of beta E-IR from cells in the pituitary lobes and in the hypothalamus is differentially regulated, but that common principles are involved. In particular, the results provide first direct evidence for an action of vasopressin as a stimulator of the release of POMC-derived peptides in the hypothalamus.
 ...
PMID:Release of beta-endorphin-immunoreactivity from rat pituitary and hypothalamus in vitro: effects of isoproterenol, dopamine, corticotropin-releasing factor and arginine8-vasopressin. 252 39

The dog pituitary pars intermedia (PI) appears to consist of relative large numbers of ACTH-containing cells in addition to the more abundant alpha MSH-containing cells. Since regulation of PI secretion probably varies across mammalian species, this study was undertaken to identify substances potentially involved in the control of dog PI POMC peptide secretion and to determine if these substances altered the secretion of immunoreactive (IR) ACTH and IR-alpha MSH in a parallel fashion. Pituitary neurointermediate lobes from dogs were collected and dispersed, and the PI cells obtained were perifused. For comparison, rat PI and pars distalis (PD) cells as well as dog PD cells were similarly collected and perifused. Dog PI cells secreted IR-alpha MSH at a basal rate of 125 +/- 59 (mean +/- SD) pg/min.10(5) cells and IR-ACTH at a rate of 40 +/- 9 pg/min.10(5) cells (molar IR-alpha MSH/IR-ACTH = 10). In contrast, secretion rates for IR-alpha MSH and IR-ACTH from perifused rat PI cells were 171 +/- 108 and 3 +/- 2 pg/min.10(5) cells, respectively (molar IR-alpha MSH/IR-ACTH = 179). Using Sephadex G-50 gel filtration chromatography, virtually all of the IR-beta-endorphin secreted by dog PI cells eluted near beta-endorphin (1-31). In addition, all of the IR-alpha MSH secreted by dog PI cells coeluted with synthetic alpha MSH on the G-50 column, but IR-ACTH appeared in two peaks, one eluting near porcine ACTH-(1-39) and another, apparently larger mol wt species. Dopamine and somatostatin were found to inhibit the secretion of IR-alpha MSH and IR-ACTH from perifused dog PI cells in a parallel and dose-dependent fashion. Norepinephrine and epinephrine similarly inhibited POMC peptide secretion, but this effect was blocked by haloperidol, suggesting that it was mediated through a dopamine receptor. CRF stimulated the secretion of both hormones from dog PI, and this effect was abolished by treatment of the cells with either dopamine or somatostatin. Cortisol had no effect on either basal or CRF-stimulated secretion of IR-alpha MSH or IR-ACTH from dog PI cells, but it did inhibit CRF-stimulated IR-ACTH from perifused dog PD. These results suggest that 1) dog PI secretes considerably more IR-ACTH than that in the rat; 2) the probable separate cell sources of IR-alpha MSH and IR-ACTH in dog PI are regulated in an identical fashion; and 3) dopamine, somatostatin, and CRF may function in the physiological or pathophysiological regulation of dog PI.
 ...
PMID:Regulation and secretion of proopiomelanocortin peptides from isolated perifused dog pituitary pars intermedia cells. 253 71

It is well established that prolactin release during exercise is one of the important factors in exercise-induced menstrual dysfunction. The purpose of this study is to clarify the mechanisms of prolactin release during exercise. Ten female athletes measured their BBT every morning. They performed incremental exercise on a cycle ergometer, with or without naloxone, on the 5th to 8th days of the follicular phase. Three minutes before the exercise, 0.4mg of naloxone was injected intravenously and a further 1.6mg/hr of naloxone was continuously infused during exercise. Blood samples were collected after 60 minutes bed rest (Rest), at the time when the heart rates reached 150 bpm (Submax), the point of exhaustion (Max) during exercise and after 60 minutes bed rest following exercise (After 1hr). The levels of prolactin in serum, dopamine, beta-endorphin. VIP and ACTH in the plasma were measured. Whereas prolactin increased significantly at Submax (p less than 0.05) and Max (p less than 0.001), the increase in prolactin was suppressed by the administration of naloxone (p less than 0.05). Dopamine showed no remarkable change during exercise, with or without naloxone. There were significant increases in beta-endorphin at Max (p less than 0.001), VIP at Submax and Max (p less than 0.001), but these increases were suppressed by the administration of naloxone (p less than 0.001). ACTH which had markedly increased at Submax (p less than 0.025) and Max (p less than 0.001) showed a slight tendency to decrease following the administration of naloxone, but there were no significant differences in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Effect of naloxone on hormonal changes during exercise. 255 87

The ability of desenkephalin-gamma-endorphin (DE gamma E; ORG5878) to antagonise a raised limbic dopamine function was investigated in the rat and common marmoset. Dopamine was infused for 13 days directly into the nucleus accumbens of the rat and ventral striatum of the marmoset and increased locomotor activity. Such increases in both the rat and marmoset were antagonised by the subcutaneous injection of DE gamma E, administered in a range 10-500 micrograms/kg (t.i.d.), during the 13 day period of infusion of dopamine. Treatment with dopamine alone or in combination with DE gamma E failed to influence the level of spontaneous locomotor activity after discontinuing treatment. In contrast, in experiments performed in the rat, the level of spontaneous locomotor activity was increased 2- to 3-fold after cessation of a regimen of infusion of dopamine and haloperidol. The increases in activity were antagonised by DE gamma E (50 and 100 micrograms/kg t.i.d., s.c., for 2 days). In additional experiments in the marmoset, using animals initially selected as "high activity" responders to challenge with (-)N-n-propylnorapomorphine, the infusion of dopamine caused a reversal in responsiveness to the stimulant effects of (-)N-n-propylnorapomorphine on locomotor activity some 2-4 weeks after discontinuing the infusion of dopamine. The administration of fluphenazine (0.01-2.5 mg/kg b.d.), during the infusion of dopamine, failed to prevent the subsequent change in responsiveness to (-)N-n-propylnorapomorphine, whereas a regimen of dopamine and DE gamma-E (25-100 micrograms/kg t.i.d.) prevented such changes.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Desenkephalin-gamma-endorphin is an antagonist of the hyperactivity response induced by infusion of dopamine into the nucleus accumbens of rat and ventral striatum of marmoset. 257 24

Over many years a large number of studies have demonstrated that nicotine and exposure to cigarette smoke produce marked neuroendocrine changes in animals and in man. The initial effects of nicotine are characterized by a marked hypersecretion of ACTH, vasopressin, beta-endorphin, prolactin and LH. Many of these very acute stimulatory effects of nicotine rapidly disappear, probably due to a desensitization of the central nicotinic cholinergic receptors involved. Instead, upon acute intermittent treatment with nicotine or exposure to cigarette smoke, an inhibition of prolactin, LH and TSH secretion occurs, which is associated with maintained hypersecretion of corticosterone. These effects are probably mediated via activation of central cholinergic receptors of the ganglionic type. Evidence indicates that the inhibitory effects of nicotine on LH and prolactin secretion are produced via an activation by these nicotinic receptors of the tubero-infundibular dopamine neurons, releasing dopamine as a prolactin inhibitory factor. Dopamine inhibits LHRH release via an axonic interaction involving D1-like dopamine receptors in the median eminence. It therefore seems possible that the reduced fertility found in heavy smokers may be counteracted by D1 receptor antagonists. The symptoms associated with glucocorticoid hypersecretion induced by nicotine is discussed considering not only the peripheral side effects but also permanent deficits in hippocampal glucocorticoid receptors and loss of hippocampal neurons. In view of the important influence of hormones on immune functions, it seems likely that smoking will cause disturbances in immune responsiveness. Finally, the nicotine-induced alterations of neuroendocrine function, especially in the pituitary-adrenal axis and in vasopressin release, may also lead to behavioural consequences in smokers, especially in the withdrawal phase.
 ...
PMID:Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications. 266 Jan 82

1. Preliminary, general chemical characteristics of substances in artificial sea water (ASW) washed through stimulated body wall (SBW) and in hemolymph taken from noxiously stimulated animals (SHL) were consistent with those of classical neurotransmitters, amino acids, and small- to medium-sized peptides. 2. 5-Hydroxytryptamine (5HT) and acetylcholine (ACh), unlike SBW and SHL, caused relaxation when perfused into isolated body wall. FMRFamide produced a biphasic response--brief contraction followed by prolonged relaxation. 3. Small cardioactive peptide (SCPB) caused body wall contractions similar to those produced by SBW and SHL, except that SCPB contractions displayed more desensitization and were completely blocked by 30 mM CoCl2. SCPB and SBW contractions were synergistic. 4. Dopamine caused persistent body wall contractions similar to those of SBW and SHL. Dopamine contractions were reduced but not blocked by 30 mM CoCl2. Unlike SBW activity, dopamine activity was reduced by alkalinization. 5. Glutamate and taurine produced strong but usually short-lasting body wall contractions. Adenosine, octopamine, arginine vasotocin, and cholecystokinin (CCK-8) caused weak or variable contractions. Met-enkephalin and somatostatin caused no obvious body wall responses. 6. When superfused over the fully sheathed abdominal ganglion, FMRFamide, met-enkephalin, glutamate, aspartate, and taurine reduced the magnitude of the gill-withdrawal reflex elicited by siphon nerve stimulation. 7. Taken together with earlier results, these data suggest a preliminary framework for trauma signal pathways. It is proposed that stress hormones (perhaps including FMRFamide, SCPs, 5HT, and dopamine) are released into hemolymph from neuroendocrine cells. Effective amounts of active intracellular solutes such as amino acids may also be released by extensive cellular rupture. Various humoral signals produce slow effects that contribute to hemostasis, balling up, increased cardiac output, and reflex suppression.
 ...
PMID:Humoral factors released during trauma of Aplysia body wall. II. Effects of possible mediators. 276 Feb 88

No immunoreactive axons were detected with an antiserum against tyrosine hydroxylase in the rabbit intermediate lobe (IL), which thus appears to be devoid of dopaminergic (DA) innervation. Dopamine and its agonists, which classically inhibit alpha-MSH release have no inhibitory effects on rabbit IL superfused in vitro but, paradoxically, stimulate alpha-MSH release. D2 type DA receptors, known to mediate inhibitory control of dopamine on melanotropic cells, and detectable by their affinity for (3H)-spiroperidol, were as previously reported absent from the rabbit IL. The absence of (3H)-spiroperidol binding sites in the IL was further confirmed on rabbit pituitary sections by radioautography. The mechanism of DA stimulation is still not clear, but might be tentatively explained by interference with other receptors involved in the stimulation of the gland. The lack of DA inhibitory control over the rabbit IL is an exception among the species so far studied.
 ...
PMID:Absence of inhibitory dopaminergic control of the rabbit pituitary gland intermediate lobe. 286 83

To further our understanding of the functional role of catecholaminergic systems in regulating hypothalamic corticotropin-releasing hormone (CRH) secretion, we assessed the direct effects of a multiplicity of catecholamine agonists and antagonists on hypothalamic CRH secretion. To accomplish this, we used an in vitro rat hypothalamic organ culture system in which CRH secretion from single explants was evaluated by a specific RIA (IR-rCRH). Norepinephrine (NE) stimulated IR-rCRH secretion dose dependently, with peak effects in the nanomolar range. The effect of NE was antagonized by the mixed alpha antagonist phentolamine, the alpha 1 antagonist prazosin, and the alpha 2 antagonist yohimbine, but not by the beta blocker, L-propanolol. Compatible with these data were the findings that the alpha 1 agonist phenylephrine and the alpha 2 agonist clonidine both stimulated IR-rCRH secretion in a dose-dependent fashion. On the other hand, whereas the beta agonist, isoproterenol, caused a weak, non-dose-dependent increase in IR-rCRH secretion, this effect could not be antagonized by L-propanolol. Despite pretreatment with serotonin and acetylcholine antagonists, the effect of NE upon IR-rCRH secretion was undiminished, suggesting that NE-induced CRH secretion is not mediated by either neurotransmitter. On the other hand, pretreatment with gamma-aminobutyric acid (GABA) attenuated NE-induced IR-rCRH secretion. Whereas epinephrine (E) stimulated IR-rCRH secretion, this occurred only at higher concentrations, and was antagonized by phentolamine, but not by L-propanolol. Dopamine (DA) had a weak stimulatory effect that could be antagonized by the DA1 receptor antagonist, SCH 23390, but not by phentolamine. We conclude that NE and E stimulate hypothalamic IR-rCRH secretion via alpha 1 and alpha 2 receptors. The effect of NE upon IR-rCRH secretion is not apparently mediated by serotonergic or cholinergic interneurons, but is modulated by the inhibitory neurotransmitter, GABA. These data support the idea that the central catecholaminergic systems are excitatory rather than inhibitory upon CRH secretion when acting directly at the hypothalamic level.
 ...
PMID:Catecholamine effects upon rat hypothalamic corticotropin-releasing hormone secretion in vitro. 290 33

The effects of dopamine on proopiomelanocortin (POMC) gene expression were compared in primary cultures of the anterior and intermediate lobes of the rat pituitary. A single-stranded POMC complementary DNA was used to quantitate POMC messenger RNA levels. Treatment with dopamine (1 microM) for 48 h reduced POMC messenger RNA levels in the intermediate lobe by 77%, but had no effect on POMC gene expression in the anterior lobe. Dopamine D2 receptors were implicated in the response, as bromocriptine (100 nM). reproduced the dopamine inhibition. The responses to dopamine and bromocriptine were antagonized by haloperidol (10 microM). The decrease in POMC messenger RNA levels was dose dependent with ED50 values of about 50 and 0.1 nM for dopamine and bromocriptine, respectively. The accumulation of POMC-derived peptides, beta-endorphin and alpha-melanocyte-stimulating hormone, over 2 days was measured by radioimmunoassay and was shown to parallel the changes in POMC synthesis. The dopamine-induced inhibition of intermediate lobe POMC synthesis was unaffected by isoprenalin (5 microM) and corticotropin-releasing factor (10 nM), although these treatments had stimulatory effects when tested alone. Activating adenylate cyclase with forskolin (1 microM) or treatment with 8-bromocyclic adenosine monophosphate (1 mM) doubled POMC messenger RNA levels, and, when tested against these stimuli, bromocriptine still produced a 30% inhibition of POMC gene expression. These observations suggest that D2 receptor induced inhibition of POMC gene expression is not only mediated by a decrease in cyclic adenosine monophosphate levels. When cells were pretreated with pertussis toxin (100 ng/ml), the bromocriptine-induced inhibition was almost completely lost, suggesting that the dopaminergic inhibition is mediated by guanosine triphosphate binding proteins.
 ...
PMID:Dopamine inhibition of proopiomelanocortin gene expression in the intermediate lobe of the pituitary. Interactions with corticotropin-releasing factor and the beta-adrenergic receptors and the adenylate cyclase system. 296 67

The purpose of this study was to better assess the function of catecholamine-containing nerve terminals in the pituitary pars intermedia lobe. Hypothalamohypophyseal explants, which included the intact mediobasal hypothalamus (MBH), median eminence, infundibular stalk and the neurointermediate lobe, were obtained from 2-3-week-old male and female albino rats. The tissue was placed in a perfusion chamber and maintained under physiological conditions for up to 12 h. A set of bipolar stimulating electrodes was positioned on the surface of the median eminence, infundibular stalk or the rostroventral arcuate nucleus of the MBH. A microelectrode recorded electrical activity in the pars intermedia gland. Two types of spontaneous action potentials were found; fast 2-4 ms duration neural fiber type spikes and slower 7-10 ms duration spikes probably derived from non-neural endocrine cells. Single-pulse electrical stimulation at all 3 sites evoked both kinds of potentials, while trains of stimuli (0.1-20 Hz) decreased or completely inhibited the basal firing rate of the slower ones. Application of the neuroleptic. L-sulpiride (0.01, 0.1 or 1.0 mumol), to the perfusion medium increased the spontaneous endocrine cell activity and blocked the stimulus-induced inhibition in the explants but had no effect on the activity in isolated pituitaries. Dopamine (0.1 mumol), which is known to inhibit the secretion of pro-opiomelanocortin peptides, reversibly suppressed the spontaneous endocrine cell potentials. These observations support a hypothesis for the presence of a functional tuberohypophyseal dopamine inhibitory system and a possible, but as yet unidentifiable, excitatory system in the pars intermedia. Thus, hypothalamohypophyseal explants can be used to elucidate specific information on this type of neuroendocrine axis.
 ...
PMID:The hypothalamohypophyseal system in vitro: electrophysiology of the pars intermedia and evidence for both excitatory and inhibitory inputs. 298 82


<< Previous 1 2 3 4 5 6 7 8 Next >>